Clinical Research Directory

Inclusion Criteria: 1. Adults ≥18 years old. 2. Patient understands the purpose, the potential risks as well as benefits of the trial and is willing to participate in all parts of the follow-up. 3. Patient has given written consent to participate in the trial. 4. Patients presenting with NSTE/ACS documented in an emergency department or cath lab fulfilling the NSTE/ACS definition of the ESC guidelines (18, 20). 5. Patients undergoing PCI for the index NSTE/ACS. 6. Reference index vessel diameter between 2.5-4.2 mm and length ≤28mm by visual estimation. 7. Lesion preparation by either manual thrombectomy or pre-dilatation has been successful, with opening of the vessel and Thrombolysis in Myocardial Infarction (TIMI) flow \>2 and residual stenosis \<20%. 8. Culprit lesion treatment only in the index procedure with planned implantation of one only RMS. 9. Patients who have no contraindication for.dual antiplatelet therapy (DAPT). Exclusion Criteria: 1. A known hypersensitivity or contraindication to any of the following: aspirin, heparin, ticagrelor, prasugrel, bivalirudin, clopidogrel, scaffold material, contrast media, sirolimus. 2. Ongoing infection, including active endocarditis. 3. NSTE/ACS due to in stent/scaffold thrombosis/restenosis. 4. Severely tortuous, angulated or calcified coronary arteries resulting in not successful pre-dilatation or complication as described in exclusion criteria 10. 5. Culprit vessel left main. 6. Ostial target lesion (within 5.0 mm of vessel origin). 7. Bifurcation target lesions Medina 1,1,1 with upfront planned 2-stent technique. 8. Bifurcation side branch target lesions Medina 0,0,1. 9. Known thrombocytopenia (PLT\<100,000/mm3). 10. Unsuccessful pre-dilatation, defined as a residual stenosis rate more than 20%, estimated by any method and/or angiographic complications (e.g. distal embolization, side branch closure, extensive dissections). 11. Culprit lesion requiring preparation with technique other than semi/non-compliant and/or cutting/scoring balloons (eg rotational/orbital atherectomy, shockwave lithotripsy). 12. Planned PCI in more lesions than the culprit one at the index procedure. 13. Culprit vessel located or supplied by bypass graft. 14. Life expectancy less than 1 year. 15. Active severe bleeding (Bleeding Academic Research Consortium classification ≥III) (21). 16. Cardiogenic shock. 17. Major surgery planned into the next 6 months that requires double antiplatelet treatment discontinuation. 18. Diffuse severe coronary artery disease that will require coronary artery bypass grafting (CABG) planned in the next 6 months. 19. Chronic kidney disease with eGFR\<15 ml/min or under dialysis. 20. Enrolment in another study that competes or interferes with this study. 21. Subject will not be able to comply with the follow-up requirements according to investigators' opinion. 22. Pregnant or breast-feeding females or females who intend to become pregnant during the time of the study.